B+
Bull case
20%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
ENLV
EnlivexFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Focused spending may preserve resources for a successful Phase IIb readout, while realizable RAIN-treasury value could offer upside. Both outcomes remain unproven.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
A roughly 60% workforce reduction could disrupt trial execution or yield less savings than expected. [#SEC-6K-2026-10-19] SEC filing
Momentum
87
Value
62
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.17 · Bull $0.32 · Bear $0.05Analysis 2026-10-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $80.00
Why
Momentum87 · Δ7d -
Value62 · Δ7d -0.3
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • A roughly 60% workforce reduction could disrupt trial execution or yield less savings than expected. [#SEC-6K-2026-10-19] SEC filing
- • Convertible-note cash obligations and variable-price conversion create liquidity and dilution risk. [#SEC-6K-2026-08-11] SEC filing
- • Trial-funding needs, possible restructuring disruption, variable-price note conversion, and volatile or illiquid digital assets could overwhelm clinical upside.
Catalyst clock
2026-10-27
1-for-16 reverse share split
Lead driver: Value · See fundamentals
Momentum
87
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
62
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+17.4
Sentiment
0
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 87.4 / Value 61.5 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.17
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.05
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$3.24M
Beta
1.61
Shares Out
19.91M
P/E (TTM) · Derived
0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.03
Rev YoY
-
EPS YoY
-11884.6%
Gross Margin
-
Op Margin
-
Net Debt
-$5.23M
Current Ratio
193.24
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data